SCHEMBL5163846

SCHEMBL5163846

NC(=O)Cc1c[nH]c2c1ccc1ccccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 1/20 0.50
CSNK2B P67870 1/20 0.50
CSNK2A1 P68400 1/20 0.50
MPO P05164 3/20 0.47
GAA P10253 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ICMT O60725 7/20 0.43
ALDH1A1 P00352 4/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
KDM4E B2RXH2 2/20 0.42
MAPT P10636 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
HPGD P15428 2/20 0.42
SLC6A2 P23975 1/20 0.40
FNTA P49354 1/20 0.40
FNTB P49356 1/20 0.40
LMNA P02545 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32684019 0.78 HTR2A (0.60) MPOGAANPSR1ICMT
SCHEMBL32684012 0.78 MPO (0.50) MPOGAANPSR1ICMTSMN1; SMN2
SCHEMBL3611008 0.78 HTR2A (0.60) MPOGAANPSR1ICMTMEN1
SCHEMBL8088111 0.78 HTR2A (0.60) MPOGAANPSR1ICMT
SCHEMBL1973303 0.78 MPO (0.74) MPOGAANPSR1ICMTLMNA
SCHEMBL17521783 0.78 GPR84 (0.56) CSNK2A2CSNK2BCSNK2A1MPOALDH1A1
SCHEMBL3262116 0.77 MAPT (0.68) MPOGAANPSR1ICMTALDH1A1
SCHEMBL40822 0.77 MAPT (0.68) MPOGAANPSR1ICMTALDH1A1
SCHEMBL29376364 0.77 MAPT (0.68) MPOGAANPSR1ICMTALDH1A1
SCHEMBL31369561 0.77 MAPT (0.66) CSNK2A2CSNK2BCSNK2A1MPONPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1358156-B1 BENZ(G) INDOLES AND THEIR USE AS SPLA2 INHIBITORS LILLY CO ELI (US) 2007-02-21 EP disclosed
US-6916840-B2 Spla2 inhibitors ELI LILLY AND COMPANY (US) 2005-07-12 US disclosed
US-20040063967-A1 Novel spla2 inhibitors BEIGHT DOUGLAS WADE (US) 2004-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063967-A1 Novel spla2 inhibitors PLA2G12A, SPINT2, PLA2G4A CSNK2A2 1671/4885CSNK2B 3339/4885CSNK2A1 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.